PhoreMost and Plexxikon Collaborate to Identify Novel Drug Targets

News   Apr 16, 2018 | Original story from PhoreMost

 
PhoreMost and Plexxikon Collaborate to Identify Novel Drug Targets

Dr Chris Torrance, CEO at PhoreMost Ltd

 
 
 

RELATED ARTICLES

UCL Technology Fund Investment MeiraGTx Raises $75 Million in IPO

News

MeiraGTx Holdings plc raised $75 million of gross proceeds upon close of the company’s initial public offering (IPO).

READ MORE

Diagnosis and Treatment of Heart and Circulatory Diseases a Top Priority for the UK

News

NHS commits to a new focus around heart and circulatory diseases in 10 year plan

READ MORE

A Mechanism of Drug Resistance in Breast & Ovarian Cancer

News

Researchers have discovered the molecular means by which some cancers caused by errors in the gene BRCA1 evade treatment by drugs custom-tailored to kill them.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma Drug Discovery Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE
 

We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy